Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo

Published:2012-03 Issue:3 Volume:102 Page:444-449
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Gurtner Kristin,Hessel Franziska,Eicheler Wolfgang,Dörfler Annegret,Zips Daniel,Heider Karl-Heinz,Krause Mechthild,Baumann Michael

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference46 articles.

1. CD44v6: a target for antibody-based cancer therapy;Heider;Cancer Immunol Immunother,2004

2. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells;Günthert;Cell,1991

3. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat;Screaton;J Biol Chem,1993

4. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons;Screaton;Proc Natl Acad Sci U S A,1992

5. Antimitotic activity of the potent tumor inhibitor maytansine;Remillard;Science,1975

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Investigation into the In Vitro Targeted Killing of CD44-Expressing Triple-Negative Breast Cancer Cells Using Recombinant Photoimmunotherapeutics Compared to Auristatin-F-Based Antibody-Drug Conjugates;Molecular Pharmaceutics;2024-07-24

2. The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: Robust gene signature correlates with radiotherapy outcome in patients and xenografts;Radiotherapy and Oncology;2024-02

3. CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies;Frontiers in Immunology;2023-10-03

4. Cancer stem cells (CSCs): key player of radiotherapy resistance and its clinical significance;Biomarkers;2023-01-02

5. Insight of nanomedicine strategies for a targeted delivery of nanotherapeutic cues to cope with the resistant types of cancer stem cells;Journal of Drug Delivery Science and Technology;2021-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3